Document Detail

Imaging of castration-resistant prostrate cancer: development of imaging response biomarkers.
MedLine Citation:
PMID:  23422587     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: The current standard for imaging castration-resistant prostate cancer (CRPC) focuses solely on detection. However, in order to assess treatment response, imaging must provide quantitative results that can be validated.
RECENT FINDINGS: Bone scintigraphy remains the most commonly used imaging tool for CRPC in bone, but with limited quantification capabilities. Both PET and MRI provide quantitative measures that could be used to assess treatment response. Several PET tracers have been shown to be able to detect bone metastases, but more research regarding their use for treatment response assessment is necessary. Similarly, research has shown that diffusion-weighted and dynamic contrast-enhanced MRI can detect metastases, with some studies suggesting that they may be suitable for assessing treatment response.
SUMMARY: Recent research has shown that many imaging techniques are able to successfully detect metastases in CRPC patients as well as or better than standard imaging. These imaging methods can also be applied to treatment response assessment; however, more research must be done to validate the quantitative measures before these techniques can be used clinically for assessing patients.
Courtney Morisson; Robert Jeraj; Glenn Liu
Related Documents :
18289977 - Information loss recovery for block-based image coding techniques-a fuzzy logic approach.
11325507 - Life and reference.
10883967 - Multiresolution spot detection by means of entropy thresholding.
2367657 - Effect of axial loading on neural foramina and nerve roots in the lumbar spine.
11011867 - Laser-induced afterimages in humans.
11155817 - Antisense imaging: where are we now?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current opinion in urology     Volume:  23     ISSN:  1473-6586     ISO Abbreviation:  Curr Opin Urol     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-03     Completed Date:  2013-09-24     Revised Date:  2014-03-20    
Medline Journal Info:
Nlm Unique ID:  9200621     Medline TA:  Curr Opin Urol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  230-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgen Antagonists / therapeutic use
Antineoplastic Agents, Hormonal / therapeutic use
Bone Neoplasms / diagnosis*,  metabolism,  secondary*,  therapy
Contrast Media / diagnostic use
Drug Resistance, Neoplasm
Magnetic Resonance Imaging
Molecular Imaging* / methods
Multimodal Imaging
Neoplasms, Hormone-Dependent / diagnosis*,  metabolism,  therapy
Positron-Emission Tomography
Predictive Value of Tests
Prostatic Neoplasms / pathology*,  therapy
Radiopharmaceuticals / diagnostic use
Tomography, X-Ray Computed
Tumor Markers, Biological / metabolism*
Whole Body Imaging
Grant Support
Reg. No./Substance:
0/Androgen Antagonists; 0/Antineoplastic Agents, Hormonal; 0/Contrast Media; 0/Radiopharmaceuticals; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development and characterization of a novel plug and play liquid chromatography-mass spectrometry (L...
Next Document:  Psychosocial aspects of active surveillance.